Costs and Benefits of Trastuzumab for Breast Cancer in Singapore
Author Information
Author(s): Gilberto Jr de Lima Lopes
Primary Institution: Johns Hopkins Singapore International Medical Centre
Hypothesis
What are the societal costs and benefits of treatment with trastuzumab in patients with early HER2-positive breast cancer in Singapore?
Conclusion
Treatment with adjuvant trastuzumab is likely to generate net societal economic benefits in Singapore.
Supporting Evidence
- Trastuzumab significantly improves disease-free and overall survival in early HER2-positive breast cancer.
- Incremental costs in Singapore were estimated at $26,971.05.
- Average cost per QALY was $19,174.59.
Takeaway
This study looks at how much money society gains or loses when using a specific breast cancer drug called trastuzumab. It finds that using this drug is likely to be beneficial for society overall.
Methodology
The study estimated societal costs and benefits by analyzing direct and indirect costs associated with trastuzumab treatment, using data from four treatment centers in Singapore.
Potential Biases
Using GNP per capita as a measure of productivity may introduce bias as it is not age and gender specific.
Limitations
The study relies on previously published cost-effectiveness studies rather than developing an independent model specific to Singapore.
Participant Demographics
Patients with early HER2-positive breast cancer in Singapore.
Statistical Information
Confidence Interval
95% confidence intervals were calculated based on QALYs gained.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website